Stage IV Adult Diffuse Small Cleaved Cell Lymphoma (DBCOND0028713)

Identifiers

Synonyms
Not Available

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT00489203
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancersupportive_care2completed
NCT01233921
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancersupportive_careNot Availablecompleted
NCT00293345
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed
NCT00054483
Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunctionbasic_science1completed
NCT00608361
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgerytreatment1completed
NCT01045928
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1terminated
NCT01129193
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphomatreatment1completed
NCT01558778
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNo drug interventionssupportive_careNot Availablewithdrawn
NCT00354185
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomatreatment1terminated
NCT00025415
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunctiontreatment1completed
NCT01805037
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomastreatment1 / 2terminated
NCT00003970
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphomatreatment1completed
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomastreatment1 / 2active_not_recruiting
NCT01158274
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumorstreatment1completed
NCT00098891
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomastreatment1completed
NCT01199562
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantNot AvailableNot Availablecompleted
NCT00010192
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancertreatment1completed
NCT00101244
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphomatreatment1terminated
NCT01159067
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overloadsupportive_care2terminated
NCT00049504
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancertreatment2completed
NCT00891072
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgerytreatment1completed
NCT00040846
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignanciestreatment2completed
NCT00060112
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphomatreatment1terminated
NCT00017381
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphomatreatment0completed
NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplantsupportive_careNot Availablecompleted
NCT00019708
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphomatreatment1terminated
NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplanttreatment0completed
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancertreatment2terminated
NCT00096005
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1terminated
NCT00799461
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsNo drug interventionssupportive_care3completed
NCT00089011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00499811
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunctiontreatment1completed
NCT00112593
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancertreatmentNot Availablecompleted
NCT00089271
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomastreatment1completed
NCT00856388
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisorderstreatmentNot Availablecompleted
NCT00769288
FAU in Treating Patients With Advanced Solid Tumors or LymphomaNo drug interventionstreatment1completed
NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomatreatmentNot Availablecompleted
NCT00348985
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomastreatment1completed
NCT01076270
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciestreatmentNot Availableterminated
NCT00118170
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Functiontreatment1completed
NCT00004241
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcomatreatment1completed
NCT01273766
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignanciessupportive_care2completed
NCT00458731
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytomatreatment1completed
NCT00275080
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemiatreatment1completed
NCT00105001
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancertreatment2completed
NCT00795769
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplantsupportive_care2completed
NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignanciessupportive_care2completed
NCT00077155
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphomatreatment1completed